
Clinical UpdatesanbenitamabHB1801
Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial Review
By MedXY|Sep 6, 2026
This review synthesizes evidence from a phase 3 trial demonstrating improved pathological complete response rates with neoadjuvant anbenitamab and HB1801 in ERBB2-positive breast cancer, highlighting efficacy, safety, and clinical implicati